Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gaucher disease: pediatric concerns.

Deborah Elstein1, Aya Abrahamov, Altoon Dweck

  • 1Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel. gaucher@szmc.org.il

Paediatric Drugs
|June 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease.

International journal of molecular sciences·2026
Same author

Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical Studies.

Journal of clinical medicine·2026
Same author

Excess Risk of Monoclonal Gammopathy in Patients With Gaucher Disease.

American journal of hematology·2026
Same author

Monoclonal Gammopathy of Undetermined Significance.

The New England journal of medicine·2025
Same author

MyGauch<sup>TM</sup>: a patient-centered digital health app for Gaucher disease.

mHealth·2025
Same author

A large long-term database of Gaucher disease patients demonstrates increased risk of lymphoma and myeloma, but not of solid tumours.

Internal medicine journal·2025
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
Same journal

Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

Paediatric drugs·2026
See all related articles

Gaucher disease, a prevalent lysosomal storage disorder, presents diverse symptoms and is diagnosed by enzyme activity and genetic mutation analysis. Enzyme replacement therapy improves many symptoms but not neurological aspects, prompting research into alternative treatments like gene therapy.

Area of Science:

  • Genetics
  • Biochemistry
  • Pediatrics

Background:

  • Gaucher disease is the most common autosomal recessive lysosomal storage disorder.
  • Diagnosis relies on reduced acid beta-glucosidase activity and molecular mutation analysis for prognostication.
  • Phenotypic heterogeneity is significant, especially in non-neuronopathic type I.

Purpose of the Study:

  • To review the diagnosis, genetic basis, and current and emerging treatments for Gaucher disease.
  • To highlight the impact of specific mutations on disease severity and neurological involvement.
  • To discuss the efficacy and limitations of enzyme replacement therapy and explore alternative therapeutic strategies.

Main Methods:

  • Review of diagnostic criteria including enzyme assays and molecular genetic testing.

Related Experiment Videos

  • Analysis of genotype-phenotype correlations for various Gaucher disease mutations.
  • Evaluation of current therapeutic interventions, including enzyme replacement therapy (ERT) and symptomatic management.
  • Exploration of novel treatment modalities such as substrate reduction therapy, bone marrow transplantation, and gene therapy.

    • Main Results:

    • Specific mutations (e.g., N370S, 84GG, IVS2+1, L444P) are linked to varying disease severity and neurological involvement.
    • Enzyme replacement therapy effectively reduces visceral organ volume, improves hematological parameters, and promotes growth in children.
    • ERT does not reverse neurological deficits, requires lifelong infusions, and is costly.
    • Symptomatic management and emerging therapies like gene therapy offer potential for improved outcomes, particularly for neuronopathic forms.

    Conclusions:

    • Gaucher disease management requires a multi-faceted approach considering genetic background and clinical presentation.
    • While ERT has transformed care for many, its limitations necessitate the development of alternative and potentially curative therapies.
    • Gene therapy and bone marrow transplantation hold promise for addressing the underlying causes and neurological manifestations of Gaucher disease.